BACKGROUND & AIMS: The relationship between serum peginterferon pharmacokinetics and pharmacodynamics and the early virologic response (EVR) to peginterferon and ribavirin therapy was assessed in patients with chronic hepatitis C virus (HCV) genotype 1 infection. METHODS: A total of 333 patients (160 African Americans [AA] and 173 Caucasian Americans [CA]) who received peginterferon alpha-2a (180 microg/wk) without a dose modification during the initial 4 weeks of therapy were analyzed. Peginterferon and 2,5-oligoadenylate synthetase (2,5-OAS) serum levels were measured on days 0, 1, 2, 3, 7, 14, 28, 56, 84, and 168 of treatment. The EVR (>or=2-log(10) decline in HCV RNA levels by week 12 of therapy) was the primary virologic end point. RESULTS: Peginterferon pharmacokinetics after the first dose were similar in AA and CA, but AA had greater peginterferon concentrations at days 1, 3, 14, and 28 (P < .05). AA had higher absolute serum 2,5-OAS levels on days 0, 1, 2, 3, 7, 14, 28, and 56 (P < .05), but the magnitude of 2,5-OAS induction during treatment were similar. AA patients showed a smaller decline in serum HCV RNA during the first 28 days of treatment (P < .001) and a lower EVR (65% vs 83%). AA and CA with EVR had significantly higher serum peginterferon concentrations and serum 2,5-OAS induction during the first 12 weeks than patients without an EVR. CONCLUSIONS: Peginterferon alpha-2a pharmacokinetic and pharmacodynamic variability is associated with EVR in both AA and CA with HCV infection, but do not explain the racial disparity in combination treatment efficacy.
BACKGROUND & AIMS: The relationship between serum peginterferon pharmacokinetics and pharmacodynamics and the early virologic response (EVR) to peginterferon and ribavirin therapy was assessed in patients with chronic hepatitis C virus (HCV) genotype 1 infection. METHODS: A total of 333 patients (160 African Americans [AA] and 173 Caucasian Americans [CA]) who received peginterferon alpha-2a (180 microg/wk) without a dose modification during the initial 4 weeks of therapy were analyzed. Peginterferon and 2,5-oligoadenylate synthetase (2,5-OAS) serum levels were measured on days 0, 1, 2, 3, 7, 14, 28, 56, 84, and 168 of treatment. The EVR (>or=2-log(10) decline in HCV RNA levels by week 12 of therapy) was the primary virologic end point. RESULTS: Peginterferon pharmacokinetics after the first dose were similar in AA and CA, but AA had greater peginterferon concentrations at days 1, 3, 14, and 28 (P < .05). AA had higher absolute serum 2,5-OAS levels on days 0, 1, 2, 3, 7, 14, 28, and 56 (P < .05), but the magnitude of 2,5-OAS induction during treatment were similar. AA patients showed a smaller decline in serum HCV RNA during the first 28 days of treatment (P < .001) and a lower EVR (65% vs 83%). AA and CA with EVR had significantly higher serum peginterferon concentrations and serum 2,5-OAS induction during the first 12 weeks than patients without an EVR. CONCLUSIONS: Peginterferon alpha-2a pharmacokinetic and pharmacodynamic variability is associated with EVR in both AA and CA with HCV infection, but do not explain the racial disparity in combination treatment efficacy.
Authors: Heather J Ribaudo; David W Haas; Camlin Tierney; Richard B Kim; Grant R Wilkinson; Roy M Gulick; David B Clifford; Catia Marzolini; Courtney V Fletcher; Karen T Tashima; Daniel R Kuritzkes; Edward P Acosta Journal: Clin Infect Dis Date: 2005-12-27 Impact factor: 9.079
Authors: M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis Journal: N Engl J Med Date: 1999-08-19 Impact factor: 91.245
Authors: Xiao-Song He; Xuhuai Ji; Matthew B Hale; Ramsey Cheung; Aijaz Ahmed; Yaqian Guo; Garry P Nolan; Lawrence M Pfeffer; Teresa L Wright; Neil Risch; Robert Tibshirani; Harry B Greenberg Journal: Hepatology Date: 2006-08 Impact factor: 17.425
Authors: Marcelo Silva; Jorge Poo; Frank Wagner; Mary Jackson; David Cutler; Michael Grace; Ronald Bordens; Connie Cullen; Joann Harvey; Mark Laughlin Journal: J Hepatol Date: 2006-04-18 Impact factor: 25.083
Authors: Milton W Taylor; Takuma Tsukahara; Leonid Brodsky; Joel Schaley; Corneliu Sanda; Matthew J Stephens; Jeanette N McClintick; Howard J Edenberg; Lang Li; John E Tavis; Charles Howell; Steven H Belle Journal: J Virol Date: 2007-01-31 Impact factor: 5.103
Authors: P Glue; R Rouzier-Panis; C Raffanel; R Sabo; S K Gupta; M Salfi; S Jacobs; R P Clement Journal: Hepatology Date: 2000-09 Impact factor: 17.425
Authors: E S A Araújo; H Dahari; A U Neumann; N de Paula Cavalheiro; C E Melo; E S de Melo; T J Layden; S J Cotler; A A Barone Journal: J Viral Hepat Date: 2011-04 Impact factor: 3.728
Authors: Charles D Howell; Alexis Gorden; Kathleen A Ryan; Alexander J Thompson; Chadi Ibrahim; Michael Fried; Nezam H Afdhal; John G McHutchison; Kevin V Shianna; David B Goldstein; Alan R Shuldiner; Braxton D Mitchell Journal: J Hepatol Date: 2011-10-23 Impact factor: 25.083
Authors: Runyan Jin; Ling Cai; Ming Tan; John G McHutchison; Thomas C Dowling; Charles D Howell Journal: Am J Gastroenterol Date: 2012-10-23 Impact factor: 10.864